The peptide market has grown faster than the information around it. To anyone paying attention right now, it can feel like there are only two camps: one made up of podcasters, DTC websites, and online forums run by vendors aggressively promoting compounds and promising outlandish benefits — and on the other side, a medical establishment that can come across as dismissive of the entire category. Neither represents the full picture. The reality is more nuanced, more interesting, and more useful to someone trying to assess whether peptide therapy could make sense for them.

A Legitimate Drug Class With a Noise Problem

A peptide is a short chain of amino acids — the same building blocks that make up proteins, linked together in smaller sequences. The distinction between a peptide and a protein is essentially one of size: chains of up to roughly 50 amino acids are classified as peptides; longer chains that fold into complex three-dimensional structures are proteins.1 That size difference matters pharmacologically. Peptides are small enough to penetrate tissues efficiently, specific enough to bind to targeted receptors with precision, and structurally simple enough to be synthesized and modified in a laboratory setting. These properties are what make them interesting to medicine.

The human body produces approximately 7,000 known endogenous peptides — meaning peptides the body makes itself — that regulate virtually every biological system.2 Insulin is a peptide. So are endorphins, oxytocin, and glucagon-like peptide-1, the hormone your gut releases after a meal to signal satiety to your brain — and the same hormone that GLP-1 drugs like semaglutide are designed to mimic. Peptides govern blood sugar, immune response, tissue repair, sleep, pain, and metabolism. They are not a fringe concept. They are one of the body's primary signaling languages.

Medicine has been harnessing peptides therapeutically for over a century, beginning with the isolation of insulin in 1921. Today, more than 100 peptide-based drugs have received FDA approval, spanning oncology, endocrinology, cardiovascular disease, and metabolic disorders.3,4 Roughly 170 more are currently in active clinical trials.5 The FDA approved 34 peptide drugs in the eight years between 2016 and 2024 alone — a pace that reflects both the maturation of peptide synthesis technology and the commercial validation that drugs like semaglutide have delivered for the entire class.4

The category has a long and credible track record in medicine. But peptide is not a quality standard. It is a molecular description. The explosive growth of interest in peptides — driven by influencers, biohacking podcasts, and DTC wellness companies — has rapidly expanded the market, pulling compounds with very different profiles under the same umbrella. Compounds with decades of human safety data are now discussed in the same breath as substances that have never been tested in a single human being. The result is a market where the same label, "peptide therapy," can describe a rigorously studied pharmaceutical drug or an uncharacterized powder synthesized overseas and shipped in a vial with a "for research purposes only" disclaimer stamped on the label.

To evaluate any peptide honestly, you have to start by understanding where on the spectrums of safety and efficacy it actually sits.

Three Categories. Not Interchangeable.

These three categories define where a compound sits in the regulatory and evidence landscape. They are not interchangeable. The confusion between them — the assumption that something available from an online vendor operates under the same standards as a physician-prescribed compounded medication — is where most of the risk in this space originates.

Category One

FDA-Approved Peptide Drugs

These are compounds that have completed the full clinical development process — Phase 1, 2, and 3 trials establishing safety and efficacy in humans for a specific indication — and received FDA approval for prescription use. They are manufactured under current Good Manufacturing Practice (cGMP) standards, meaning every batch is subject to strict quality controls, sterility testing, and potency verification. Once approved, a physician can prescribe them for their labeled indication or for any other use they judge to be clinically appropriate — a common and legal practice known as off-label prescribing. Examples include tesamorelin (approved for HIV-associated lipodystrophy),11,12 bremelanotide (approved for hypoactive sexual desire disorder), and semaglutide (approved for type 2 diabetes and obesity).

On safety — manufacturing

FDA-approved drugs are manufactured under cGMP standards — the most stringent manufacturing framework in pharmaceuticals, as defined and enforced by the FDA.14 The risk of receiving a product that is not what it claims to be, at the dose it claims, is as close to zero as the industry can achieve.

On safety — the compound itself

Achieving FDA approval requires demonstrating an acceptable human safety profile across Phase 1, 2, and 3 clinical trials. That safety record is documented, published, and applicable to the drug regardless of the indication for which it is prescribed. This is the gold standard on both fronts.

On efficacy

The evidence is strongest for the approved indication — that is what the trials were designed to demonstrate. When a physician prescribes off-label, efficacy becomes a matter of clinical judgment rather than established proof. That judgment belongs to the physician.

Category Two

Physician-Prescribed Compounded Medications

Compounding is the practice of a licensed pharmacy preparing a medication for an individual patient under a physician's prescription — adjusting dose, formulation, or delivery method to meet that patient's specific needs. A 503A compounding pharmacy — the federal designation for pharmacies licensed to compound medications for individual patients — operates under USP standards. The United States Pharmacopeia (USP) is the independent scientific body that sets quality, purity, and manufacturing standards for pharmaceuticals and compounded medications in the United States.15 The highest tier of compounding pharmacy quality is PCAB accreditation — certification by the Pharmacy Compounding Accreditation Board, the independent body that verifies a pharmacy meets quality and safety standards beyond the minimum federal requirements.16

Compounded peptide medications are not FDA-approved in their compounded form, but they are not operating outside the regulatory system either. The pharmacy handles the product. The physician handles the patient — reviewing their history, evaluating the clinical rationale, and taking legal and medical responsibility for every prescription they sign.

On safety — manufacturing

A well-run 503A compounding pharmacy operates under USP standards with defined requirements for sterility, potency, and quality control. This is meaningfully rigorous — the manufacturing risk is low and well-controlled. It is not identical to cGMP pharmaceutical manufacturing, but it is categorically different from anything in the gray market. The product you receive from a licensed 503A pharmacy is, with high confidence, what it claims to be at the dose it claims.

On safety — the compound itself

This depends on which compound is being prescribed. A compounded version of a previously FDA-approved drug carries that drug's existing human safety record with it. A compound with a well-established preclinical safety profile but limited human data sits in a different position. This is where the physician's expertise matters — evaluating the compound-level safety profile against your specific health history, labs, and risk tolerance is a clinical judgment, not a general one.

On efficacy

The compound has typically been studied — but not always in your specific situation, for your specific goal, at your specific dose. That gap is where the physician's clinical judgment applies the available evidence to your individual context rather than a general population.

Category Three

The Gray Market

The gray market refers to compounds sold online — typically labeled "research use only" or "not for human consumption" — by vendors with no prescribing authority, no pharmacy licensure, and no manufacturing oversight of any kind. These labels are a legal strategy, not a safety framework. They exist to help vendors avoid FDA scrutiny, not to protect the buyer.

This is where the majority of the podcast discourse about peptides lives. BPC-157, CJC-1295, TB-500, ipamorelin — the compounds dominating the online conversation — are gray market products. Some have animal data behind them. Some have none. Most have no controlled human trial data at all. None have received FDA approval, and several have been flagged by the FDA for serious safety concerns.5,6 That history rarely makes it into the marketing.

On safety — manufacturing

There are no manufacturing standards. No sterility testing. No dose accuracy verification. No regulatory oversight of any kind. A third-party certificate of analysis — the document gray market vendors use to signal quality — covers roughly two of the twelve quality checkpoints a regulated pharmaceutical product must pass.7 The other ten go unverified.

Data Point

A 2026 analysis of 6,441 gray market peptide samples found that between 41.6% and 71.1% failed basic purity and dose accuracy standards — and a clean purity result did not predict a clean endotoxin result. Endotoxins are bacterial byproducts that can trigger serious immune reactions when injected.7

On safety — the compound itself

Largely unknown in humans for most compounds in this category. Some have preclinical toxicology studies suggesting wide safety margins at doses far exceeding typical use — in some cases 100 to 1,000 times higher — with no lethal dose established.8,9 That is a real and relevant data point. But the absence of controlled human trials means long-term safety, drug interactions, and population-level risk remain genuinely uncharacterized.

On efficacy

Also largely unknown in humans for most compounds in this category. History shows that animal studies showing promising results have repeatedly failed to translate when the same compounds were tested in people. Dramatic claims circulating online are almost entirely built on preclinical data, anecdote, and extrapolation.

How to Evaluate Any Peptide

Understanding the three categories tells you where a compound sits in the regulatory landscape. It does not tell you whether a specific compound is worth using. For that, you need to ask three questions — the same three questions a physician works through when evaluating whether a compound belongs in a clinical protocol.

First: Is there a credible biological mechanism? A mechanism means a documented explanation for how a compound produces its claimed effect — ideally at the receptor level, tracing a specific chain of events from binding to biological response to measurable outcome. Not every effective drug has a fully characterized mechanism — medicine has a long history of compounds that worked before we fully understood why. But for compounds without robust human trial data, a credible mechanism is one of the few things that separates a reasonable hypothesis from a marketing claim. Vague functional language — "supports recovery," "promotes healing" — is not a mechanism. A compound that cannot explain how it does what it claims deserves more scrutiny, not less.

Second: Is there human evidence? Animal studies generate hypotheses. They do not establish that something works in humans. Compounds that show clear promise in rodent models routinely fail to produce the same results in humans — the biology differs enough that this is not the exception, it is the norm.5 The only credible proof that something works in humans is controlled human trial data — and for most compounds dominating the gray market conversation today, that is something in short supply. What many of these compounds do have is an abundance of anecdotal data which, when aggregated, has some utility to a clinician. But not all human evidence carries the same weight, and understanding the difference between a controlled trial and a collection of user reports is precisely what a physician is there to interpret.

Third: What does the safety data actually show? A compound is not simply "safe" or "dangerous." What matters is what the available data actually establishes, and what it leaves open. The absence of human clinical data does not mean a compound is dangerous — it means its safety profile in humans has not been formally characterized. Those are meaningfully different statements. For some compounds, formal preclinical toxicology studies have administered 100 to 1,000 times a typical human use dose in animal models without establishing a lethal dose at all.8,9 That does not tell you something won't cause harm over the long-term or that it won't interact with other medications, but it is a real and relevant lower bound on acute toxicity risk. For other compounds, clinical development was halted because participants died — a data point of an entirely different character. Understanding which situation a specific compound is in, and what that means for a specific patient's risk profile, is a clinical judgment. It is not something a label or a certificate of analysis can answer.

Comparison Point

Creatine has over 3,000 indexed trials on PubMed.10 Most gray market peptides have zero controlled human trials. Both are sometimes discussed in the same category — "performance supplements" — as if the evidence base is comparable. It is not.

Here is the thing about these three questions: answering them is not a casual exercise. It requires access to primary literature that most people do not know how to find or interpret, an understanding of pharmacokinetics and receptor biology, familiarity with the clinical trial record of related compounds, and the ability to weigh all of it against a specific individual's health history, labs, existing medications, and goals. The information is publicly accessible. The judgment about what it means for a specific person is not.

This is not an argument for deference. It is an argument for expertise. Building a peptide regimen that maximizes benefit while minimizing risk requires an experienced physician who can evaluate your individual circumstances, work through these questions thoughtfully, and provide personalized direction — on the record.

Where We Stand

The only legitimate route to peptide therapy is under the guidance of a physician, sourced from a PCAB-accredited 503A pharmacy. This is not the cautious option. This is not the expensive option. This is the only option that delivers what a results-oriented person actually wants from this category: a compound designed for human use, identified by a licensed physician as the best fit for your specific biology, goals, and health history — sourced from a pharmacy operating under verified quality standards that is inspected by the FDA. Not a research chemical. Not a vial with a disclaimer. A legitimate medical protocol, built around you.

Every compound in the Pompton Labs formulary must meet the following criteria before we make it available:

Once a compound is on the formulary, every patient goes through a physician-led intake before anything is dispensed. A licensed physician reviews your health history, relevant lab work, and goals — and makes an independent clinical determination of whether the protocol is appropriate for you specifically. From there, the relationship continues. The same physician stays with you, conducts structured check-ins to assess how you're responding, remains available as questions arise, and adjusts your protocol as needed.

We are aware that a number of popular peptides do not currently meet the standard we've established and therefore are not eligible to be a part of our formulary at this time. If the regulatory picture changes or the evidence base matures, we will update our offerings accordingly — but we will not move the standard to meet the market. There are plenty of companies in this space willing to sell you just about anything. We are not one of them.